by Meriem Bouslouk-Marx | Jul 18, 2022 | News
In the current draft of the Act on the Stabilisation of Finances for the Statutory Health Insurance in Germany, the threshold for orphan drugs shall decrease from currently €50 to €20m. A déjà vu? But wasn’t it €30m last time this was mentioned? Would €25m be a...
by Meriem Bouslouk-Marx | Jun 1, 2022 | News
Back on stage! This year’s RAPS Euro Convergence in Amsterdam gave Dr. Meriem Bouslouk-Marx the floor to outline the interdependencies of EU and national legislative reviews. She analysed the implications of potential changes of the EU Orphan legislation such as...
by Meriem Bouslouk-Marx | Feb 28, 2022 | News
Oral and maxillofacial surgery was one major discipline during my last years of dental medicine at the Friedrich Schiller University in Jena. I was intrigued by the strange names of diseases and syndromes such as Hodgkin’s, non-Hodgkin’s and...
by Meriem Bouslouk-Marx | Mar 15, 2021 | News
With Advanced Therapy Medicinal Products (ATMPs), especially those for the treatment of rare diseases – innovative but also very expensive therapies – entering the market, a new challenge for payers has arisen. How can innovative medicinal products be financed in the...
by Meriem Bouslouk-Marx | Jul 15, 2020 | News
The International Federation of Pharmaceutical Manufacturers & Associations IFPMA, the European Federation of Pharmaceutical Industries and Associations EFPIA and the German Association of Research-Based Pharmaceutical Companies vfa organised an online event to...
